Baker Bros. Advisors LP Galapagos Nv Transaction History

Baker Bros. Advisors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$68.86 - $83.34 $769,854 - $931,741	-11,180 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$96.85 - $148.25 $119,319 - $182,644	-1,232 Reduced 9.93%	11,180 $1.11 Million
Q3 2020 Nov 16, 2020	SELL	$122.47 - $213.56 $80,830 - $140,949	-660 Reduced 5.05%	12,412 $1.76 Million
Q4 2019 Feb 14, 2020	SELL	$146.12 - $215.82 $1.75 Million - $2.59 Million	-12,000 Reduced 47.86%	13,072 $2.7 Million
Q4 2018 Feb 13, 2019	SELL	$87.81 - $110.65 $18.6 Million - $23.5 Million	-212,119 Reduced 89.43%	25,072 $2.3 Million

Q3 2018 Nov 14, 2018	SELL	$90.63 - $120.22 $2.06 Million - $2.73 Million	-22,703 Reduced 8.74%	237,191 $26.7 Million
Q3 2017 Nov 14, 2017	BUY	$73.17 - $103.47 $19 Million - $26.9 Million	259,894	259,894 $26.4 Million

16.5M

77.1K

57.2K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.63B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.